Research progress of Osimertinib acquired resistance / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
;
(12): 105-112, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-1015105
ABSTRACT
Osimertinib, as a representative of the third generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has significant curative effect for EGFR T790M mutation type non-small cell lung cancer (NSCLC). But with the development of clinical research Osimertinib's resistance gradually appear. How to deal with the resistance is a problem that the clinical workers must focus on. This article will review the latest research progress of the mechanisms and the solutions of osimertinib acquired resistance.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Clinical Pharmacology and Therapeutics
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS